Outsourcing in Clinical Trials Europe 201421-22 May 2014, Brussels, Belgium
The OCT team would like to thank you for making the 2013 event such a huge success.
Earlier this year 250 industry professionals attended OCT Europe to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical outsourcing challenges.
Covering all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques, this year’s agenda boasted presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty from across Europe.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
Outsourcing in Clinical Trials East Coast boasts a fantastic exhibition of outsourcing service providers and industry specialists. Our exhibition area is already filling up due to the fantastic event which took place at earlier this year.
Our production team will soon begin research to develop the 2014 agenda. Catering both to small to mid-sized biotech and pharma as well as the larger companies, this 2014 event will include a stream which offers content relevant to the company types separately.
C3 Jian has initiated the first Phase II clinical study for its C16G2, which selectively targets a cavity-causing organism Streptococcus mutans, under its US Food and Drug Administration investigational new drug (IND) application.
BioLineRx has completed the dose-escalation stage of the ongoing Phase I/II clinical study for BL-7010, a non-absorbable, orally available polymer intended for treatment of celiac disease.
Novartis has announced that the Phase III study of Jakavi (ruxolitinib) has met its primary endpoint of maintaining haematocrit control (red blood cell volume) without the need for phlebotomy and reducing spleen size in patients with polycythemia ver…
Ireland-based biopharmaceutical firm Alkermes has started a major clinical development programme for ALKS 5461, a once-daily, oral investigational medicine with a new mechanism of action for the adjunctive treatment of major depressive disorder (MDD)…
Israel-based Kamada has started a Phase II/III clinical study of its proprietary human Alpha-1 Antitrypsin (AAT) 'Glassia' for the treatment of newly diagnosed paediatric patients with type 1 diabetes (T1D).